Peptide

CagriSema (cagrilintide + semaglutide)

Novo Nordisk's dual amylin/GLP-1 co-formulation. Phase 3 showed 23% weight loss but failed to beat tirzepatide head-to-head. FDA submission pending.

Editor approved

Summary What is CagriSema, and how well does it work for weight loss? Read the full summary ↓

CagriSema is one injection combining cagrilintide and semaglutide, two medicines that reduce hunger in different ways. Semaglutide is a GLP-1 medicine, meaning it helps control appetite and blood sugar; cagrilintide copies amylin, a hormone that helps you feel full and slows digestion. In one type 2 diabetes study, people lost 14.2% of their weight and reduced HbA1c, a blood sugar measure, by up to 1.91 points. In another study, people lost 23% of their weight after 84 weeks, but CagriSema did not perform as well as tirzepatide at the highest tested dose. The combination is not FDA-approved yet, although its application is under review, and the evidence is mixed.

What this means for you: CagriSema has shown substantial weight loss, but it has not beaten tirzepatide in direct testing. It is not yet approved, so there is not enough reason to seek it outside medical care.

conflicting evidence

Research snapshot Phase 3 complete, FDA submission pending

Updated 2026-09-06

Phase 3 complete with two large trials. FDA submission filed. Evidence tier 2 (approved drug-class combination with phase 3 data). Downgraded from tier 1 because not yet FDA-approved and failed head-to-head vs tirzepatide.

Evidence tierTier 2, Strong human evidence, hard endpoints or biomarkers

Last verified2026-09-05

CagriSema is a fixed-dose co-formulation of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), developed by Novo Nordisk. It targets two complementary gut-hormone pathways: amylin slows gastric emptying and reduces glucagon, while GLP-1 increases insulin secretion and reduces appetite.

The REIMAGINE 2 trial (February 2026) showed HbA1c reduction up to 1.91 points and 14.2% weight loss in type 2 diabetes. In the open-label head-to-head REDEFINE 4 (February 2026), CagriSema produced 23% weight loss at 84 weeks but failed to show non-inferiority versus tirzepatide 15 mg, a significant competitive setback.

Novo Nordisk filed CagriSema with the FDA for weight loss in late 2025. The filing is under review as of August 2026. The combination of two approved drug classes (amylin + GLP-1) in a single injection is pharmacologically sound, unlike most peptide stacks which combine unapproved research chemicals.

The key differentiator versus standalone GLP-1 therapy is the amylin component, which adds satiety signaling through a different receptor pathway. However, the failure to beat tirzepatide in head-to-head comparison limits the clinical case for switching from an approved triple agonist to a dual.

CagriSema is not yet FDA-approved. Both components are prescription drugs, not research chemicals. Cagrilintide alone (without semaglutide) is also in development but has not been approved as a standalone product.

Related in the encyclopedia

Further reading